Moderna, Inc. filed an 8-K on May 1, 2026, announcing its first quarter financial results for the period ended March 31, 2026. The announcement was made via a press release furnished as Exhibit 99.
Perrigo Company plc (PRGO) announced the completion of the sale of its Dermacosmetics Business to Karo Healthcare, an affiliate of Karo Healthcare AB and an investment vehicle managed by an affiliate...
Amgen (AMGN) filed an 8-K on April 30, 2026, reporting its unaudited results of operations and financial condition for the first quarter of 2026 (ended March 31, 2026).
Halozyme Therapeutics announced the appointment of Darren Snellgrove as its new Chief Financial Officer, effective June 8, 2026.
Alnylam Pharmaceuticals announced its financial results for the first quarter of 2026 in an 8-K filing with the SEC on April 30, 2026.
Merck & Co., Inc. filed an 8-K on April 30, 2026, reporting its first-quarter 2026 financial results. The filing includes a press release (Exhibit 99.1) and supplemental information (Exhibit 99.
AbbVie filed an 8-K on April 29, 2026, announcing its financial results for the first quarter of 2026, which ended March 31, 2026.
Teva Pharmaceutical Industries Ltd. announced its first quarter 2026 financial results and a definitive agreement to acquire Emalex Biosciences in an 8-K filing on April 29, 2026.
Ionis Pharmaceuticals, Inc. (IONS) filed an 8-K on April 29, 2026, announcing its financial results for the quarter ended March 31, 2026.
Regeneron Pharmaceuticals filed an 8-K on April 29, 2026, announcing its financial and operating results for the first quarter of 2026, which ended March 31, 2026.